Pharmacodynamic and kinetic basis for the selection of pneumococcal resistance in the upper respiratory tract
- PMID: 12556434
- DOI: 10.1093/jac/dkf510
Pharmacodynamic and kinetic basis for the selection of pneumococcal resistance in the upper respiratory tract
Abstract
The oropharynx is both the reservoir where antibiotic-resistant Streptococcus pneumoniae strains are selected and the focus for further spread of these organisms. In order to select antibiotic-resistant organisms, the antibiotic must be able to eradicate the susceptible population. How an antibiotic acts on oropharyngeal flora is not fully understood, although data on salivary antibiotic concentrations could be useful for establishing some correlation. Many beta-lactam antibiotics are very active against S. pneumoniae, and although their saliva concentrations are very low, there may be enough to eradicate the majority of beta-lactam-sensitive strains. Other antibiotics achieve salivary concentrations in the range 10-30% of serum concentrations (erythromycin, clindamycin, doxycycline and rifampicin), and are also able to eradicate the antibiotic-susceptible population. Antibiotics achieving higher salivary concentrations (>/=40% of the serum levels) are not very active against S. pneumoniae (ciprofloxacin) or are able to eradicate antibiotic-sensitive and -intermediate strains (clarithromycin, azithromycin and telithromycin). Only antibiotics for which there are no highly resistant pneumococcal strains, for instance some beta-lactams administered at very high dose and for a short course, are associated with a lower risk of antibiotic resistance selection. To diminish the risk, the antibiotics should be dosed in order to obtain inhibitory quotients (maximal serum concentration/MIC ratios) >/= 4, which depends not only on the antibiotic concentration achieved but also on the lack of highly resistant organisms.
Similar articles
-
Selection of resistance of telithromycin against Haemophilus influenzae, Moraxella catarrhalis and streptococci in comparison with macrolides.J Antimicrob Chemother. 2004 Aug;54(2):542-5. doi: 10.1093/jac/dkh339. Epub 2004 Jun 23. J Antimicrob Chemother. 2004. PMID: 15215227
-
In vitro antibacterial activity of beta-lactams and non-beta-lactams against Streptococcus pneumoniae isolates from Sydney, Australia.Pathology. 2006 Aug;38(4):343-8. doi: 10.1080/00313020600820732. Pathology. 2006. PMID: 16916725
-
Pharmacodynamic target attainment potential of azithromycin, clarithromycin, and telithromycin in serum and epithelial lining fluid of community-acquired pneumonia patients with penicillin-susceptible, intermediate, and resistant Streptococcus pneumoniae.Int J Infect Dis. 2009 Jul;13(4):483-7. doi: 10.1016/j.ijid.2008.08.016. Epub 2008 Nov 28. Int J Infect Dis. 2009. PMID: 19046911
-
Therapeutic options for pneumococcal pneumonia in Turkey.Clin Ther. 2005 Jun;27(6):674-83. doi: 10.1016/j.clinthera.2005.06.009. Clin Ther. 2005. PMID: 16117975 Review.
-
Antibiotic consumption and resistance selection in Streptococcus pneumoniae.J Antimicrob Chemother. 2002 Dec;50 Suppl S2:27-37. doi: 10.1093/jac/dkf504. J Antimicrob Chemother. 2002. PMID: 12556431 Review.
Cited by
-
Molecular epidemiology of pneumococcal colonization in response to pneumococcal conjugate vaccination in children with recurrent acute otitis media.J Clin Microbiol. 2005 Jan;43(1):74-83. doi: 10.1128/JCM.43.1.74-83.2005. J Clin Microbiol. 2005. PMID: 15634953 Free PMC article. Clinical Trial.
-
Optimising treatments for sexually transmitted infections: surveillance, pharmacokinetics and pharmacodynamics, therapeutic strategies, and molecular resistance prediction.Lancet Infect Dis. 2020 Aug;20(8):e181-e191. doi: 10.1016/S1473-3099(20)30171-7. Epub 2020 Jun 19. Lancet Infect Dis. 2020. PMID: 32569625 Free PMC article. Review.
-
A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints.Infection. 2009 Aug;37(4):296-305. doi: 10.1007/s15010-009-7108-9. Epub 2009 Jul 23. Infection. 2009. PMID: 19629383 Review.
-
Single-Arm Open-Label Clinical Trial of Two Grams of Aztreonam for the Treatment of Neisseria gonorrhoeae.Antimicrob Agents Chemother. 2020 Dec 16;65(1):e01739-20. doi: 10.1128/AAC.01739-20. Print 2020 Dec 16. Antimicrob Agents Chemother. 2020. PMID: 33077658 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical